Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830303) titled 'Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis' on Sept. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Wang Fengmei
Condition:
Liver Cirrhosis
Sleep Disturbance
Hepatic Encephalopathy
Intervention:
Drug: Daridorexant
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: September 2026
Target Sample Size: 180
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07830303
Publ...